Lenacapavir injection offers one-year HIV prevention

A clinical trial has shown that Lenacapavir, a yearly injection developed by Gilead Sciences, could transform HIV prevention. Unlike daily pills, this single dose offers long-term protection, making it easier for individuals to adhere to treatment. The trial involved 40 HIV-negative adults who received a 5000 mg dose. Results indicated that the drug remained effective for at least 56 weeks, with minimal side effects, primarily mild injection-site pain. If further trials confirm its safety and effectiveness, Lenacapavir could improve access to HIV prevention, especially for those with limited healthcare options. This could significantly reduce new HIV infections globally.